Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for early stage cancer research
(Thomson Reuters ONE) -
Alacris Theranostics GmbH /
Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for
early stage cancer research
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Berlin, 14th November 2012 - Alacris Theranostics has entered into an
agreement with GlaxoSmithKline (GSK) to apply Alacris' proprietary ModCell(TM)
System, developed at the Max Planck Institute for Molecular Genetics and
licensed exclusively to Alacris, for drug stratification using data from early
stage cancer drug discovery at GSK.
GSK will provide to Alacris pre-clinical biology data from a drug discovery
project in oncology. Alacris will exploit its proprietary Systems Biology model
to determine the in silico effect of the inhibitor in its "virtual clinical
trial" system. Alacris will then suggest which cancer cell lines as well as
which cancers are more likely to respond to the inhibitor. This will be based on
whole genome and transcriptome data that is integrated in the Alacris' cancer
model ModCell(TM)
About Alacris Theranostics GmbH:
Alacris Theranostics (www.alacris.de) is a company based in Berlin specialized
in developing new approaches in personalized medicine for cancer patient
diagnosis, treatment and drug stratification. Alacris Theranostics is applying a
systems biology approach exclusively licensed as ModCell(TM) to Alacris. Based
on genome and transcriptome information obtained by next generation sequencing
and including kinetic pathway information, mutation and drug databases, the
systems biology approach is providing a "Virtual Patient" model. The "Virtual
Patient" model can predict the effect of drug treatment and optimized
combinatory treatment providing means for cancer patient stratification and for
personalized medicine approaches. In addition Alacris' "Virtual Clinical Trials"
system permits the in silico analysis of drugs, thus identifying specific
patient groups or particular genetic profiles and diseases that could be
targeted by the drug, with the goal of more efficient and precise treatment of
patients.
Contact:
Alacris Theranostics GmbH
Dr Bodo Lange, CEO
Fabeckstrasse 60-62
D-14195 Berlin
Germany
Phone: +49 30 841 312 01
Email: info(at)alacris.de
www.alacris.de
MC Services AG
Anne Hennecke, Managing Partner
Phone +49 89 210 228 18
Email: anne.hennecke(at)mc-services.eu
Press release (PDF):
http://hugin.info/155582/R/1657734/536257.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Alacris Theranostics GmbH via Thomson Reuters ONE
[HUG#1657734]
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2012 - 09:57 Uhr
Sprache: Deutsch
News-ID 203221
Anzahl Zeichen: 3452
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alacris Theranostics enters agreement with GSK to use ModCell (TM) System for early stage cancer research"
steht unter der journalistisch-redaktionellen Verantwortung von
Alacris Theranostics GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
